“The data analysis completed on the HTG EdgeSeq Reveal software was provided in a timely fashion, and the report that HTG’s bioinformaticians generated for us was detailed, complete, and easy to understand.”
Dr. Steven A. Porcelli,
Professor and Chair, Department of Microbiology & Immunology,
Weinstock Professor of Microbiology & Immunology,
Scientific Director, Einstein Flow Cytometry Core Facility,
Albert Einstein College of Medicine
Our next-generation sequencing (NGS)-adapted chemistry and instrument platforms automate sample processing and can quickly, robustly, and simultaneously profile hundreds or thousands of molecular targets from samples a fraction of the size required by competitive technologies, enabling customers to do more molecular profiling with less sample.
Hosted by HTG, the event featured a presentation by Adam Brufsky, MD, PhD (Co-Director, Comprehensive Breast Cancer Center and Medical Director, Woman’s Cancer Center at the UPMC Magee Women’s Hospital, Pittsburgh PA), who discussed the current challenges in diagnosing breast cancer and unmet medical needs and optimizing treatment. Dr. Brufsky answered questions at the conclusion of the event.
HTG Molecular Diagnostics' management team provided an update of their development plan to build a comprehensive breast cancer diagnostic platform. This plan showcased the product roadmap and milestones demonstrating the company’s progresses towards assays that can help clinicians improve the care of cancer patients.
Page last updated November 19, 2019